中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

23 records (took 0.034 seconds)

    HCV GENOTYPING AND PHENOTYPING
    2.
    发明申请
    HCV GENOTYPING AND PHENOTYPING 审中-公开
    HCV基因分型与鉴定

    公开(公告)号：US20090220943A1

    公开(公告)日：2009-09-03

    申请号：US12262111

    申请日：2008-10-30

    Applicant: Jin Hong ,  Scott Seiwert ,  Sharlene Lim ,  Xiaoli Qin

    Inventor： Jin Hong ,  Scott Seiwert ,  Sharlene Lim ,  Xiaoli Qin

    IPC: C12Q1/70 ,  C07H21/00 ,  C12P19/34 ,  C12N15/63

    CPC classification number: C12Q1/707

    Abstract: The present invention includes methods of genotyping and phenotyping HCV. In one embodiment, the methods of the invention can be used to determine whether a HCV isolate is resistant to an antiviral drug. The invention also includes primers for amplifying a HCV NS3 region and kits.

    Abstract translation: 本发明包括对HCV进行基因分型和表型的方法。 在一个实施方案中，本发明的方法可用于确定HCV分离物是否对抗病毒药物具有抗性。 本发明还包括用于扩增HCV NS3区域的引物和试剂盒。

    Inhibitors of hepatitis C virus replication
    4.
    发明授权
    Inhibitors of hepatitis C virus replication 失效
    丙型肝炎病毒复制抑制剂

    公开(公告)号：US07781474B2

    公开(公告)日：2010-08-24

    申请号：US11773912

    申请日：2007-07-05

    Applicant: Scott Seiwert ,  Leonid Beigelman ,  Lawrence M. Blatt ,  Timothy Kercher ,  April L. Kennedy ,  Steven W. Andrews

    Inventor： Scott Seiwert ,  Leonid Beigelman ,  Lawrence M. Blatt ,  Timothy Kercher ,  April L. Kennedy ,  Steven W. Andrews

    IPC: A61K31/40 ,  C07D207/00

    CPC classification number: C07D403/14 ,  C07D231/56 ,  C07D471/04

    Abstract: The embodiments provide compounds of the general Formula I, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments provide compounds of the general Formula II, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments provide compounds of the general Formula III, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

    Abstract translation: 实施方案提供了通式I的化合物，以及包含主题化合物的组合物，包括药物组合物。 实施方案提供了通式II的化合物，以及包含主题化合物的组合物，包括药物组合物。 实施方案提供了通式III的化合物，以及包含主题化合物的组合物，包括药物组合物。 实施方案还提供治疗方法，包括治疗丙型肝炎病毒感染的方法和治疗肝纤维化的方法，所述方法通常涉及向有需要的个体施用有效量的主题化合物或组合物。

    USE OF ALPHA-GLUCOSIDASE INHIBITORS TO TREAT ALPHAVIRUS INFECTIONS
    5.
    发明申请
    USE OF ALPHA-GLUCOSIDASE INHIBITORS TO TREAT ALPHAVIRUS INFECTIONS 失效
    ALPHA-GLUCOSIDASE抑制剂治疗ALVHAVIRUS感染的应用

    公开(公告)号：US20100150867A1

    公开(公告)日：2010-06-17

    申请号：US12617676

    申请日：2009-11-12

    Applicant: Lawrence M. BLATT ,  Hua TAN ,  Scott SEIWERT

    Inventor： Lawrence M. BLATT ,  Hua TAN ,  Scott SEIWERT

    IPC: A61K31/445 ,  A61P31/14 ,  A61K31/70 ,  A61K31/702 ,  A61K38/21 ,  A61K31/7056

    CPC classification number: A61K31/7008 ,  A61K31/445 ,  A61K31/7034 ,  A61K38/21 ,  A61K45/06 ,  A61K2300/00

    Abstract: The present invention provides methods for treating a flavivirus infection, including hepatitis C virus (HCV) infection, in an individual suffering from a flavivirus infection. In some embodiments, the methods involve administering to an individual in need thereof an effective amount of an agent that inhibits enzymatic activity of a membrane-bound α-glucosidase inhibitor. In other embodiments, the methods involve administering to an individual in need thereof effective amounts of an α-glucosidase inhibitor and at least one additional therapeutic agent.

    Abstract translation: 本发明提供了在患有黄病毒感染的个体中治疗黄病毒感染（包括丙型肝炎病毒（HCV）感染）的方法。 在一些实施方案中，所述方法包括向有需要的个体施用有效量的抑制膜结合的α-葡糖苷酶抑制剂的酶活性的试剂。 在其它实施方案中，所述方法包括向有需要的个体施用有效量的α-葡糖苷酶抑制剂和至少一种另外的治疗剂。

    Synthetic hyperglycosylated, and hyperglycosylated protease-resistant polypeptide variants, oral formulations and methods of using the same
    8.
    发明申请
    Synthetic hyperglycosylated, and hyperglycosylated protease-resistant polypeptide variants, oral formulations and methods of using the same 有权

    公开(公告)号：US20060204473A1

    公开(公告)日：2006-09-14

    申请号：US11351163

    申请日：2006-02-08

    Applicant: Lawrence Blatt ,  Scott Seiwert ,  Jin Hong

    Inventor： Lawrence Blatt ,  Scott Seiwert ,  Jin Hong

    IPC: A61K38/21 ,  C07K14/56 ,  C07K14/565 ,  C07K14/57

    CPC classification number: C07K14/555 ,  A61K38/00 ,  C07K14/56 ,  C07K14/565 ,  C07K14/57 ,  Y02A50/385 ,  Y02A50/387 ,  Y02A50/393

    Abstract: The present invention provides synthetic Type I interferon receptor polypeptide agonists comprising consensus or hybrid Type I interferon receptor polypeptide agonists, containing one or more native or non-native glycosylation sites. The present invention provides synthetic Type I interferon receptor polypeptide agonists comprising consensus or hybrid Type I interferon receptor polypeptide agonists, containing one or more native or non-native glycosylation sites, as well as erythropoietin and darbepoetin alfa, each of which are linked to a penetrating peptide that facilitates translocation of a substance across a biological barrier as well as pharmaceutical compositions, including oral formulations, of the same. The present invention further provides oral formulations of hyperglycosylated or protease-resistant, hyperglycosylated polypeptide variants, which polypeptide variants lack at least one protease cleavage site found in a parent polypeptide, and thus exhibit increased protease resistance compared to the parent polypeptide, which polypeptide variants further include (1) a carbohydrate moiety covalently linked to at least one non-native glycosylation site not found in the parent protein therapeutic or (2) a carbohydrate moiety covalently linked to at least one native glycosylation site found but not glycosylated in the parent protein therapeutic. The present invention further provides compositions, including oral pharmaceutical compositions, comprising the synthetic Type I interferon receptor polypeptide agonist, the hyperglycosylated polypeptide variant, or the hyperglycosylated, protease-resistant polypeptide variant. The present invention further provides containers, devices, and kits comprising the synthetic Type I interferon receptor polypeptide agonist, the hyperglycosylated polypeptide variant, or the hyperglycosylated, protease-resistant polypeptide variant. The present invention further provides therapeutic methods involving administering an effective amount of an oral pharmaceutical composition comprising a synthetic Type I interferon receptor polypeptide agonist, a hyperglycosylated polypeptide variant, or a hyperglycosylated, protease-resistant polypeptide variant to an individual in need thereof.

    Use of α-glucosidase inhibitors to treat alphavirus infections
    9.
    发明授权
    Use of α-glucosidase inhibitors to treat alphavirus infections 失效
    使用α-葡萄糖苷酶抑制剂治疗甲病毒感染

    公开(公告)号：US07932267B2

    公开(公告)日：2011-04-26

    申请号：US12617676

    申请日：2009-11-12

    Applicant: Lawrence M. Blatt ,  Hua Tan ,  Scott Seiwert

    Inventor： Lawrence M. Blatt ,  Hua Tan ,  Scott Seiwert

    IPC: A01N43/40 ,  A61K31/445

    CPC classification number: A61K31/7008 ,  A61K31/445 ,  A61K31/7034 ,  A61K38/21 ,  A61K45/06 ,  A61K2300/00

    Abstract: The present invention provides methods for treating a flavivirus infection, including hepatitis C virus (HCV) infection, in an individual suffering from a flavivirus infection. In some embodiments, the methods involve administering to an individual in need thereof an effective amount of an agent that inhibits enzymatic activity of a membrane-bound α-glucosidase inhibitor. In other embodiments, the methods involve administering to an individual in need thereof effective amounts of an α-glucosidase inhibitor and at least one additional therapeutic agent.

    Abstract translation: 本发明提供了在患有黄病毒感染的个体中治疗黄病毒感染（包括丙型肝炎病毒（HCV）感染）的方法。 在一些实施方案中，所述方法包括向有需要的个体施用有效量的抑制膜结合的α-葡糖苷酶抑制剂的酶活性的试剂。 在其它实施方案中，所述方法包括向有需要的个体施用有效量的α-葡糖苷酶抑制剂和至少一种另外的治疗剂。

Patent Agency Ranking